Treats motion sickness. ANDA 91526, held by Fresenius Kabi USA. Diphenhydramine Hydrochloride.
As of Nov 22, 2026, ANDA 91526 (Diphenhydramine Hydrochloride Preservative Free), held by Fresenius Kabi USA, was first approved by FDA on Mar 26, 2013, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Diphenhydramine hydrochloride in the injectable form is effective in adults and pediatric patients, other than premature infants and neonates, for the following conditions when diphenhydramine hydrochloride in the oral form is impractical. Antihistaminic: For amelioration of allergic reactions to blood or plasma, in anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled, and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated. Motion Sickness: For active treatment of motion sickness.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 26, 2013 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Diphenhydramine Hydrochloride Preservative Free50MG/ML · injectable;injection | Diphenhydramine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters